Tocilizumab's efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine storm

J Med Virol. 2021 Jan;93(1):120-121. doi: 10.1002/jmv.26209. Epub 2020 Jun 29.

Authors

Ioannis Andrianopoulos¹, Athanasios Papathanasiou¹, Georgios Papathanakos¹, Aristeidis Chaidos², Vasilios Koulouras¹

Affiliations

¹ Intensive Care Unit, University Hospital of Ioannina, Ioannina, Greece.
² Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
COVID-19 Drug Treatment*
Cytokine Release Syndrome
Humans
Pneumonia*
SARS-CoV-2

Substances

Antibodies, Monoclonal, Humanized
tocilizumab